SCHEMBL20242005

SCHEMBL20242005

C=CCC[C@H]1CCC(=O)N1

nearest known ligand 0.36

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.33
KCNA5 P22460 1/20 0.31
CD274 Q9NZQ7 2/20 0.31
PDCD1LG2 Q9BQ51 1/20 0.31
PDCD1 Q15116 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6201429 1.00 FAAH (0.33) FAAHKCNA5CD274PDCD1LG2PDCD1
SCHEMBL6201426 1.00 FAAH (0.33) FAAHKCNA5CD274PDCD1LG2PDCD1
SCHEMBL5964151 0.89 FAAH (0.32) FAAHCD274PDCD1LG2
SCHEMBL10687327 0.82 CD274 (0.34) KCNA5CD274PDCD1LG2PDCD1
SCHEMBL18289455 0.81 KCNA5 (0.36) KCNA5CD274PDCD1LG2PDCD1
SCHEMBL4551233 0.80
SCHEMBL2031306 0.75
SCHEMBL11132099 0.74 MGLL (0.33)
SCHEMBL23906526 0.74
SCHEMBL2731412 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12180211-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2024-12-31 US disclosed
CN-110383066-B Compounds, compositions and methods 戴纳立制药公司 2023-03-31 CN disclosed
EP-3552017-B1 COMPOUNDS USEFUL AS RIPK1 INHIBITORS DENALI THERAPEUTICS INC (US) 2022-02-23 EP disclosed
US-20210332058-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2021-10-28 US disclosed
US-20210332058-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2021-10-28 US disclosed
US-11072618-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2021-07-27 US disclosed
US-11072618-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2021-07-27 US disclosed
EP-3552017-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2019-10-16 EP disclosed
US-20190300537-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2019-10-03 US disclosed
US-20190300537-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2019-10-03 US disclosed
WO-2018107060-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2018-06-14 WO disclosed
WO-2018107060-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2018-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12180211-B2 Compounds, compositions and methods BAX, CASP3, CASP8 FAAH 1807/4885KCNA5 4658/4885CD274 1321/4885
US-11072618-B2 Compounds, compositions and methods BAX, CASP3, CASP8 FAAH 1807/4885KCNA5 4658/4885CD274 1321/4885
US-20210332058-A1 Compounds, Compositions and Methods BAX, CASP3, CASP8 FAAH 1807/4885KCNA5 4658/4885CD274 1321/4885
US-20190300537-A1 Compounds, Compositions and Methods BAX, CASP3, CASP8 FAAH 1807/4885KCNA5 4658/4885CD274 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.